Renaissance Technologies
LAB icon

Renaissance Technologies’s Standard BioTools LAB Stock Holding History

Renaissance Technologies’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-201,000
Closed -$388K – 3753
2024
Q3 		$388K Sell
201,000
-803,558
-80% -$1.57M ﹤0.01% 2888
2024
Q2 		$1.78M Sell
1,004,558
-249,300
-20% -$609K ﹤0.01% 1949
2024
Q1 		$3.4M Buy
1,253,858
+214,258
+21% +$517K 0.01% 1673
2023
Q4 		$2.3M Buy
1,039,600
+426,200
+69% +$910K ﹤0.01% 1868
2023
Q3 		$1.78M Sell
613,400
-11,909
-2% -$31.1K ﹤0.01% 1934
2023
Q2 		$1.21M Buy
625,309
+289,009
+86% +$570K ﹤0.01% 2350
2023
Q1 		$656K Buy
336,300
+36,200
+12% +$71.5K ﹤0.01% 2725
2022
Q4 		$351K Sell
300,100
-44,000
-13% -$54.2K ﹤0.01% 3155
2022
Q3 		$379K Buy
344,100
+112,200
+48% +$170K ﹤0.01% 3083
2022
Q2 		$371K Buy
231,900
+114,400
+97% +$283K ﹤0.01% 3333
2022
Q1 		$422K Buy
117,500
+100,000
+571% +$345K ﹤0.01% 3287
2021
Q4 		$69K Buy
+17,500
New +$81.9K ﹤0.01% 3745
2021
Q1 		– Sell
-745,300
Closed -$4.47M – 3531
2020
Q4 		$4.47M Sell
745,300
-1,462,900
-66% -$9.61M ﹤0.01% 1663
2020
Q3 		$16.4M Sell
2,208,200
-1,157,800
-34% -$7.99M 0.02% 838
2020
Q2 		$13.5M Buy
3,366,000
+178,818
+6% +$623K 0.01% 1052
2020
Q1 		$8.1M Buy
3,187,182
+399,082
+14% +$1.31M 0.01% 1289
2019
Q4 		$9.7M Buy
2,788,100
+42,740
+2% +$150K 0.01% 1468
2019
Q3 		$12.7M Buy
2,745,360
+222,560
+9% +$1.75M 0.01% 1238
2019
Q2 		$31.1M Buy
2,522,800
+367,718
+17% +$4.68M 0.03% 725
2019
Q1 		$28.6M Buy
2,155,082
+914,200
+74% +$9.64M 0.03% 779
2018
Q4 		$10.7M Buy
1,240,882
+88,082
+8% +$686K 0.01% 1261
2018
Q3 		$8.63M Buy
1,152,800
+82,300
+8% +$585K 0.01% 1454
2018
Q2 		$6.38M Buy
1,070,500
+118,200
+12% +$674K 0.01% 1622
2018
Q1 		$5.56M Buy
952,300
+147,000
+18% +$965K 0.01% 1749
2017
Q4 		$4.74M Buy
805,300
+134,700
+20% +$737K 0.01% 1849
2017
Q3 		$3.38M Buy
670,600
+139,600
+26% +$587K ﹤0.01% 2005
2017
Q2 		$2.15M Buy
531,000
+54,600
+11% +$259K ﹤0.01% 2223
2017
Q1 		$2.71M Buy
476,400
+25,100
+6% +$159K ﹤0.01% 2071
2016
Q4 		$3.29M Buy
451,300
+81,000
+22% +$509K 0.01% 1941
2016
Q3 		$2.97M Buy
370,300
+110,200
+42% +$1.01M 0.01% 1959
2016
Q2 		$2.35M Buy
260,100
+152,100
+141% +$1.43M ﹤0.01% 2110
2016
Q1 		$872K Sell
108,000
-97,000
-47% -$700K ﹤0.01% 2654
2015
Q4 		$2.22M Buy
205,000
+43,488
+27% +$427K ﹤0.01% 2037
2015
Q3 		$1.31M Buy
+161,512
New +$2.54M ﹤0.01% 2236
2014
Q3 		– Sell
-49,500
Closed -$1.46M – 2876
2014
Q2 		$1.46M Buy
+49,500
New +$1.59M ﹤0.01% 1890
2014
Q1 		– Sell
-80,900
Closed -$3.1M – 2928
2013
Q4 		$3.1M Sell
80,900
-55,000
-40% -$1.62M 0.01% 1487
2013
Q3 		$2.98M Buy
135,900
+119,900
+749% +$2.36M 0.01% 1449
2013
Q2 		$279K Buy
+16,000
New +$281K ﹤0.01% 2423

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Renaissance Technologies's LAB Position: Q4 2024 in Review

Renaissance Technologies sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 201,000 shares — an estimated $388K sold.

Renaissance Technologies first reported a position in LAB in Q2 2013 and held it in 38 quarters. The position peaked at $31.1M in Q2 2019. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • Renaissance Technologies reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • Renaissance Technologies sold 201,000 Standard BioTools shares in Q4 2024, an estimated $388K.
  • Renaissance Technologies first reported a position in Standard BioTools in Q2 2013 and held it in 38 quarters.
  • Renaissance Technologies's Standard BioTools position peaked at $31.1M in Q2 2019.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.